Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome

NCT04251026 is registered in ClinicalTrials.gov with Denali Therapeutics Inc. as lead sponsor.

NCT NCT04251026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04251026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome
Lead sponsor
Denali Therapeutics Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 16, 2020
Completion date
February 28, 2031
Enrollment
47 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

mucopolysaccharidosis ii